Table 3.

Associations between cytoplasmic CD24 expression and clinicopathologic variables

CharacteristiccCD24 negativecCD24 weakcCD24 moderatecCD24 strongP
All cases
23 (15.6%)57 (38.8%)52 (35.4%)15 (10.2%)
Age
    ≤65 y15 (20.8%)28 (38.9%)23 (31.9%)6 (8.4%)0.099*
    >65 y8 (10.6%)29 (38.7%)29 (38.7%)9 (12.0%)
Dukes stage
    A10 (30.3%)12 (36.4%)10 (30.3%)1 (3%)0.002
    B5 (9.3%)27 (50%)18 (33.3%)4 (7.4%)
    C7 (14.6%)17 (35.4%)18 (37.5%)6 (12.5%)
    D1 (8.3%)1 (8.3%)6 (50%)4 (33.4%)
Tumor stage
    pT12 (22.2%)4 (44.5%)3 (33.3%)0 (0%)0.045
    pT29 (26.5%)12 (35.3%)12 (35.3%)1 (2.9%)
    pT310 (10.6%)38 (40.4%)34 (36.2%)12 (12.8%)
    pT42 (20%)3 (30%)3 (30%)2 (20%)
Nodal status
    pN015 (17%)38 (43.2%)29 (33%)6 (6.8%)0.038
    pN14 (13.8%)11 (37.9%)13 (44.9%)1 (3.4%)
    pN24 (13.3%)8 (26.7%)10 (33.3%)8 (26.7%)
Distant metastasis
    Mx22 (16.3%)56 (41.5%)46 (34.1%)11 (8.1%)0.005*
    pM11 (8.3%)1 (8.3%)6 (50%)4 (33.4%)
Grade
    12 (33.3%)1 (16.7%)3 (50%)0 (0%)0.007
    219 (16.2%)49 (41.9%)43 (36.8%)6 (5.1%)
    32 (8.3%)7 (29.2%)6 (25%)9 (37.5%)
Localization
    Left colon13 (21.7%)19 (31.7%)20 (33.3%)8 (13.3%)0.374
    Transversal colon1 (4.8%)10 (47.5%)9 (42.9%)1 (4.8%)
    Right colon4 (9.1%)21 (47.7%)16 (36.4%)3 (6.8%)
    Rectum5 (22.8%)7 (31.8%)7 (31.8%)3 (13.6%)
  • Abbreviation: cCD24, cytoplasmic CD24 expression.

  • * Fisher's exact test.

  • χ2 test for trends.

  • χ2 test.